IGI Logo

Below is quote on Gland Pharma reported Q2FY22 numbers in line with market expectation by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd   

Gland Pharma Limited reported revenue from operation at ₹1,080 crores up by 30%, YoY ₹831.5 crores in Q2FY21, Rest of the world market has done well for the company up by 59% at ₹232.2 crores while Domestic market up by 19% at ₹183.5 crores. Company reported EBITDA margins of 38% up by 100 bps and EBITDA of ₹427.8 crores up by 35% YoY on back of better profit margin and new product launch.

Company reported net profit of ₹302 crores up by 38% as compared to ₹218.9 crores in Q2FY21. PAT margins stand at 27% for the quarter.

Numbers are in line with the market expectation Rest of the world market has done well for the company and some initial signs of reversal in the US market. 

Above views are of the author and not of the website kindly read disclaimer